Loading...

Please Note

  • You must enable pop-up and redirect settings in your browser to apply for jobs Learn How
  • Salary Range is an estimated salary suggested for this role based on publically available data. It was not provided by the employer for this specific position

Senior Scientist-Preclinical Safety

Japan Novartis $80,000–$120,000/year*
Job Description

The Senior Scientist in Preclinical Safety at Novartis is expected to design and conduct preclinical safety assessments of drug candidates. The role requires a PhD in toxicology, pharmacology, or a related field, along with experience in preclinical safety evaluation. Candidates should be proficient in data analysis, risk assessment, and regulatory compliance. The role involves collaboration with cross-functional teams to ensure the safety and efficacy of drug candidates, contributing to the development of innovative therapies.

Company Info

Novartis is a global healthcare company based in Switzerland, known for its innovative approach to developing and delivering medicines. With a focus on research and development, Novartis aims to improve patient outcomes through cutting-edge therapies and solutions. The company operates in over 150 countries and is committed to sustainability and ethical business practices. Novartis invests heavily in scientific research, making it a leader in the pharmaceutical industry.

Destination Guide

Japan, an island nation in East Asia, offers a unique blend of traditional culture and modern lifestyle. Known for its rich history, stunning landscapes, and advanced technology, Japan is a hub for job opportunities, particularly in technology, healthcare, and engineering. The work culture is often characterized by dedication and teamwork. Japan offers a high standard of living, excellent public services, and a safe environment. For relocation, obtaining a work visa is essential, typically requiring a job offer from a Japanese employer. The country is welcoming to expatriates, offering various support services to ease the transition.

Loading...